NF-κB inhibition by PN (Figure 2, Section 1) synergistically restored sensitivity of resistant breast cancer cells to 4-hydroxytamoxifen (4HT), and further sensitized drug-naïve cells to 4 HT [106]. The gene discussed is NFKB1; the disease is breast carcinoma.